Compare SNDL & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNDL | BNTC |
|---|---|---|
| Founded | 2006 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 432.6M | 365.1M |
| IPO Year | 2019 | N/A |
| Metric | SNDL | BNTC |
|---|---|---|
| Price | $1.68 | $13.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $5.00 | ★ $26.00 |
| AVG Volume (30 Days) | ★ 1.9M | 260.9K |
| Earning Date | 11-04-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $683,170,243.00 | N/A |
| Revenue This Year | $5.48 | N/A |
| Revenue Next Year | $3.10 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.43 | N/A |
| 52 Week Low | $1.15 | $9.70 |
| 52 Week High | $2.89 | $17.15 |
| Indicator | SNDL | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 37.79 | 48.76 |
| Support Level | $1.57 | $11.54 |
| Resistance Level | $1.77 | $13.68 |
| Average True Range (ATR) | 0.07 | 0.79 |
| MACD | 0.02 | 0.10 |
| Stochastic Oscillator | 46.99 | 73.44 |
SNDL Inc is a private-sector liquor and cannabis retailer in Canada with retail banners that include Ace Liquor, Wine and Beyond, Liquor Depot, Value Buds, and Spiritleaf. The principal activities of the company are the retailing of wines, beers, and spirits. It comprised four reportable segments: liquor retail, cannabis retail, cannabis operations, and investments. Liquor retail includes the sale of wines, beers, and spirits through owned liquor stores. The company generates maximum revenue from liquor retail.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines. Its technology has the potential to provide a one-shot cure for a wide range of diseases that are addressed by strict ongoing treatment regimens or that have no effective treatment or only palliative care options. The Company is developing a silence and replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life threatening genetic disorder.